10-KPeriod: FY2014

IDEXX LABORATORIES INC /DE Annual Report, Year Ended Dec 31, 2014

Filed February 17, 2015For Securities:IDXX

Summary

IDEXX Laboratories, Inc. (IDXX) for the fiscal year ending December 31, 2014, reported strong revenue growth, primarily driven by its Companion Animal Group (CAG). The company emphasized its "IDEXX Diagnostic Advantage," a strategy focused on integrated diagnostic and information management solutions for veterinarians. This integrated approach aims to enhance veterinary care, improve practice efficiency, and strengthen the veterinarian-client relationship. The company's strategic shift to an all-direct sales model in the U.S. for certain products is expected to drive further revenue growth and profitability, despite some near-term transition costs. Financially, IDEXX demonstrated solid performance with increasing revenues across most segments. The company continued to invest in research and development, indicating a commitment to innovation. While facing competitive pressures, IDEXX's diversified product portfolio across veterinary diagnostics, water testing, and livestock/poultry health provides a degree of resilience. The company also managed its balance sheet effectively, utilizing its credit facilities and debt issuances to fund growth and shareholder returns through a robust share repurchase program, as they have not paid cash dividends.

Financial Highlights

53 data points
Beta

Revenue

$1.49B

54.9% Gross Margin

Net Income

$181.91M

12.2% Net Margin

EPS (Diluted)

$1.79

Total Assets

$1.38B

Cash & Equivalents

$322.54M

Free Cash Flow

$175.32M

Financial Statements
Beta
Revenue$1.49B
Cost of Revenue$669.69M
Gross Profit$816.12M
R&D Expenses$98.26M
Operating Income$260.25M
Interest Expense$15.43M
Net Income$181.91M
EPS (Basic)$1.82
EPS (Diluted)$1.79
Shares Outstanding (Basic)100.09M
Shares Outstanding (Diluted)101.50M

Key Highlights

  • 1Reported a consolidated revenue of $1.49 billion, representing a 7.9% increase over the prior year.
  • 2The Companion Animal Group (CAG) remains the primary revenue driver, with 8.0% organic revenue growth.
  • 3Transitioned to an all-direct sales strategy in the U.S. for rapid assay kits and instrument consumables, aiming to enhance customer loyalty and revenue.
  • 4Invested $98.3 million in Research and Development, representing 6.6% of total revenue, underscoring a commitment to innovation.
  • 5Maintained strong gross profit margins at 54.9%.
  • 6Repurchased approximately 4.9 million shares of common stock for $618.2 million during the year, demonstrating a commitment to shareholder returns.
  • 7Expanded international revenue by 10.8%, highlighting global growth opportunities.

Frequently Asked Questions

IDEXX Laboratories primarily develops, manufactures, and distributes products and services for the companion animal veterinary market, with significant presence in livestock/poultry, water testing, and human point-of-care diagnostics. The company operates through key segments: Companion Animal Group (CAG), Water, and Livestock, Poultry and Dairy (LPD), with smaller contributions from an 'Other' category.

For the fiscal year ended December 31, 2014, IDEXX reported revenue of $1.49 billion, a 7.9% increase year-over-year. Gross profit was $816.1 million, maintaining a gross margin of 54.9%. Net income was $182.0 million, and diluted EPS was $3.58. The company also actively engaged in share repurchases, acquiring approximately 4.9 million shares for $618.2 million.

Key risks include intense competition across all its business lines, reliance on third-party suppliers which could disrupt product availability, potential for new technological advancements by competitors, the complex regulatory environment for its products (particularly in veterinary and human diagnostics), and economic downturns that could reduce demand for its products and services. Additionally, the company faces risks related to international operations and currency fluctuations.

Effective January 1, 2015, IDEXX transitioned to an all-direct sales strategy in the U.S. for certain companion animal diagnostic products, including rapid assay test kits and instrument consumables. This move aimed to strengthen customer relationships and streamline operations, moving away from reliance on third-party distributors for these specific product categories.